 |
 |
|
|
|
| LACOSAMIDE |
 |
| (2R)-2-(acetylamino)-N-benzyl-3-methoxypropanamide. |
 |
| 175481-36-4 |
 |
| Lacosamide (LCM) is anticonvulsant in animal models and is in phase 3 assessment for epilepsy and neuropathic pain. Here we seek to identify cellular actions for the new drug and effects on recognised target sites for anticonvulsant drugs. |
 |
DESCRIPTION WHITE TO OFF-WHITE POWDER
IDENTIFICATION IR.
MELTING POINT 140 ~ 143℃
LOSS ON DRYING NOT MORE THAN 0.5%
RESIDUE ON IGNITION NOT MORE THAN 0.1%
HEAVY METALS NOT MORE THAN 20PPM
ASSAY (HPLC) NOT LESS THAN 98% (C13H18N2O3)
|
|
|
|
|
|
